Date: 2014-11-22
Type of information: Construction of new premises
Compound:
Company: AstraZeneca (UK)
Therapeutic area:
Type agreement: expansion of a manufacturing plant
Action mechanism:
Disease:
Details: * On November 21, 2014, AstraZeneca announced plans to expand its biologics manufacturing center in Frederick, Md. The more than $200 million project will increase production capacity at the facility to support AstraZeneca’s maturing pipeline, and will help position the company to keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline. Astra Zeneca\'s global biologics research and development arm, MedImmune, has a pipeline of more than 120 biologics, including more than 30 in clinical development.
AstraZeneca’s Frederick biologics manufacturing center is an FDA licensed, large-scale cell culture production facility, with hundreds of thousands of square feet of administrative, production, warehouse, laboratory and utility space. The expansion project, which is anticipated to begin in December and expected to be complete in mid-2017, will add approximately 40,000 additional square feet of manufacturing, laboratory and administrative space. The expansion is also expected to bring a total of 300 new jobs to the site.
Financial terms:
Latest news:
